February 27, 2020
Bottoms are not seeing breadth indicators stabilizing and sentiment resides inside the soul of the machines as electronic trading is totally agnostic
Q4 and FY19 results: Intellia Therapeutics (NTLA) and Sage Therapeutics (SAGE)
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.
February 26, 2020
When an upheaval strikes, it is vital how communication is a component of risk mitigation and how change is needed to propel a corporation back to a reality-based scenario.
For a public entity to attract investors, it must convey its financial and organizational “representation” in a clear, interconnected/unified and trustworthy method.
February 27, 2020
A dynamic in play, a dislocation that doesn’t let investors hide anywhere but, are we truly in correction territory after today’s freefall?
Time to look for opportunity in these bottoms – look at cash positions and tread lightly until the full extent of the outbreak is known!
I make a commitment to provide need-to-know “facts in evidence” as equity’s volatility is one tactical signal for stocks.
February 18, 2020
A scorecard of earnings of 35 covered companies The current LPS (loss per share) or net income, cash positions i.e. "runways" - is a reflection of this universe's investing "status"
December 6, 2019
Dropping -$89.03 on Thursday and is up +$4.23 or +7.91% on Friday One day removed after shares of SAGE falling -59.7%, the stock is "bouncing" higher in trading after hitting 52-week lows on Thursday.
November 3, 2019
Fate Therapeutics (FATE), Vericel (VCEL), Regenxbio (RGNX) and Ultragenyx (RARE) on 11/5; AxoGen (AXGN), Athersys (ATHX), Ionis Pharmaceuticals (IONS), Sangamo Therapeutics (SGMO), Voyager Therapeutics (VYGR), Bellicum Pharmaceuticals (BLCM) and Caladrius Biosciences (CLBS) on 11/6; Adverum Biotechnologies (ADVM), Audentes Therapeutics (BOLD) and Cellectis (CLLS) and Stemline Therapeutics (STML) on 11/7 …. and Biostage (BSTG) , BioLife Solutions (BLFS), and Applied Genetic Technologies (AGTC) on 10/12
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
© 2020 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
